Format

Send to

Choose Destination
SAGE Open Med. 2017 Feb 10;5:2050312116689519. doi: 10.1177/2050312116689519. eCollection 2017.

Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines.

Author information

1
Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
2
Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
3
Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.

Abstract

OBJECTIVE:

Ankaferd hemostat is the first topical hemostatic agent about the red blood cell-fibrinogen relations tested in the clinical trials. Ankaferd hemostat consists of standardized plant extracts including Alpinia officinarum, Glycyrrhiza glabra, Thymus vulgaris, Urtica dioica, and Vitis vinifera. The aim of this study was to determine the effect of Ankaferd hemostat on viability of melanoma cell lines.

METHODS:

Dissimilar melanoma cell lines and primary cells were used in this study. These cells were treated with different concentrations of Ankaferd hemostat to assess the impact of different dosages of the drug. All cells treated with different concentrations were incubated for different time intervals. After the data had been obtained, one-tailed T-test was used to determine whether the Ankaferd hemostat would have any significant inhibitory impact on cell growth.

RESULTS:

We demonstrated in this study that cells treated with Ankaferd hemostat showed a significant decrease in cell viability compared to control groups. The cells showed different resistances against Ankaferd hemostat which depended on the dosage applied and the time treated cells had been incubated. We also demonstrated an inverse relationship between the concentration of the drug and the incubation time on one hand and the viability of the cells on the other hand, that is, increasing the concentration of the drug and the incubation time had a negative impact on cell viability.

CONCLUSION:

The findings in our study contribute to our knowledge about the anticancer impact of Ankaferd hemostat on different melanoma cells.

KEYWORDS:

Ankaferd hemostat; anticancer; melanoma

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center